This article first appeared on GuruFocus.

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is set to release its Q3 2025 earnings on Nov 10, 2025. The consensus estimate for Q3 2025 revenue is $21.20 million, and the earnings are expected to come in at -$0.90 per share. The full year 2025's revenue is expected to be $94.34 million and the earnings are expected to be -$2.80 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 4 Warning Signs with ARCT.

Is ARCT fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) have increased from $91.31 million to $94.34 million for the full year 2025 and declined from $125.76 million to $119.63 million for 2026 over the past 90 days. Earnings estimates have improved from -$3.44 per share to -$2.80 per share for the full year 2025. However, for 2026, earnings estimates have declined from -$3.13 per share to -$3.54 per share over the same period.

In the previous quarter ending on 2025-06-30, Arcturus Therapeutics Holdings Inc's (NASDAQ:ARCT) actual revenue was $28.30 million, which beat analysts' revenue expectations of $23.05 million by 22.77%. The actual earnings were -$0.34 per share, surpassing analysts' earnings expectations of -$0.95 per share by 64.32%. Following the release of these results, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) saw a 30.73% increase in its stock price in one day.

Based on the one-year price targets offered by 9 analysts, the average target price for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is $44.78, with a high estimate of $140.00 and a low estimate of $12.00. The average target implies an upside of 440.14% from the current price of $8.29.

Based on GuruFocus estimates, the estimated GF Value for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) in one year is $14.74, suggesting an upside of 77.80% from the current price of $8.29.

Based on the consensus recommendation from 11 brokerage firms, Arcturus Therapeutics Holdings Inc's (NASDAQ:ARCT) average brokerage recommendation is currently 2.0, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.